Phloretin as an add-on therapy to losartan attenuates diabetes-induced AKI in rats: A potential therapeutic approach targeting TLR4-induced inflammation
No Thumbnail Available
Date
2023-11
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Abstract
Targeting Toll-like receptor 4 (TLR4) and Angiotensin II type 1 receptor (AT1R) could provide renoprotection during acute kidney injury (AKI) mainly by regulating inflammation, oxidative stress, mitochondrial dysfunction, and apoptosis. Phloretin (TLR4 inhibitor) as an add-on therapy to losartan (AT1R inhibitor) could provide more therapeutic benefits against AKI under diabetic condition. We aimed to study the effect of phloretin as an add-on therapy to losartan against AKI under diabetic condition.
Description
Keywords
Pharmacy, Inflammation, Phloretin, Toll-like receptor-4 (TLR4), Diabetes, Acute Kidney Injury (AKI)